Central congenital hypothyroidism

Central congenital hypothyroidism (CCH), also known as congenital secondary or tertiary hypothyroidism, is a rare endocrine disorder in which the thyroid gland itself is structurally normal but fails to produce adequate thyroid hormones due to insufficient stimulation by thyroid-stimulating hormone (TSH) from the pituitary gland (secondary) or inadequate thyrotropin-releasing hormone (TRH) from the hypothalamus (tertiary). Unlike primary congenital hypothyroidism, where the thyroid gland is absent, underdeveloped, or dysfunctional, CCH results from defects in the hypothalamic-pituitary axis. This distinction is clinically important because standard newborn screening programs that rely solely on elevated TSH levels may fail to detect CCH, as TSH levels may be low, normal, or only mildly elevated. The condition affects multiple body systems due to the critical role of thyroid hormones in growth, brain development, and metabolism. Key clinical features include prolonged neonatal jaundice, poor feeding, lethargy, hypotonia, growth retardation, and delayed psychomotor development. If untreated, CCH can lead to significant intellectual disability and short stature. Some patients may present with additional pituitary hormone deficiencies (combined pituitary hormone deficiency), which can cause hypoglycemia, micropenis in males, and adrenal insufficiency. CCH may occur as an isolated finding or as part of broader syndromes involving pituitary developmental abnormalities, such as septo-optic dysplasia or pituitary stalk interruption syndrome. CCH can be caused by mutations in several genes, including TSHB (encoding the TSH beta subunit), TRHR (TRH receptor), IGSF1, TBL1X, IRS4, and transcription factor genes involved in pituitary development such as POU1F1, PROP1, HESX1, LHX3, LHX4, SOX3, and OTX2. Treatment consists of lifelong levothyroxine (L-T4) replacement therapy, with dosing guided by free T4 levels rather than TSH, since TSH is an unreliable marker in central hypothyroidism. Early diagnosis and prompt initiation of treatment are essential to prevent neurodevelopmental impairment. Patients with combined pituitary hormone deficiencies require additional hormone replacement therapies as indicated.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Central congenital hypothyroidism